Breaking Finance News

Zacks Investment Research downgraded Myovant Sciences Ltd (NASDAQ:MYOV) to Sell in a report released today.

Zacks Investment Research has downgraded Myovant Sciences Ltd (NASDAQ:MYOV) to Sell in a report released on 6/21/2017.

Yesterday Myovant Sciences Ltd (NASDAQ:MYOV) traded -0.64% lower at $11.26. The company’s 50-day moving average is $12.59 and its 200-day moving average is $12.15. The last closing price is down 2.65% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 30,568 shares of the stock traded hands, up from an average trading volume of 29,400

See Chart Below

Myovant Sciences Ltd (NASDAQ:MYOV)

Myovant Sciences Ltd has a 52 week low of $10.25 and a 52 week high of $14.27 The company’s market cap is currently $0.

General Information About Myovant Sciences Ltd (NASDAQ:MYOV)

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.